He also previously served as chief commercial officer at Spark Therapeutics, Inc., where he spearheaded the launch of global commercial operations, and patient advocacy, market access, and medical affairs efforts for Luxturna. Vivaldi served as executive vice president and chief global therapeutics officer at Bioverativ Inc., where he was responsible for building and managing their commercial organization, including sales and marketing efforts for the franchise’s lead products, until it was acquired by Sanofi S.A.

Vivaldi is currently the president and chief executive officer of Sigilon Therapeutics, Inc., where he also serves as a member of the company’s board of directors. As we advance our expanding portfolio of novel therapeutics for multiple rare endocrine diseases, we are looking forward to leveraging his skills and experience building commercial enterprises to ensure we are prepared to deliver treatments to patients worldwide.”ĭr.

Vivaldi’s expertise in global commercial operations, coupled with his passion for meeting the needs of patients with rare diseases, make him a natural fit for Crinetics. Scott Struthers, Ph.D., founder and chief executive officer of Crinetics, stated, “Dr. Vivaldi comes to Crinetics with over two decades of experience as a physician and industry executive with deep expertise commercializing pharmaceuticals, especially those treating rare and orphan diseases, in the U.S. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of Rogério Vivaldi Coelho, M.D., M.B.A. SAN DIEGO – Janu– Crinetics Pharmaceuticals, Inc.

Vivaldi board